Proteinuria
137
12
14
71
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
15 trials with published results (11%)
Research Maturity
71 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
8.0%
11 terminated out of 137 trials
86.6%
+0.0% vs benchmark
36%
50 trials in Phase 3/4
21%
15 of 71 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 71 completed trials
Clinical Trials (137)
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
Huaier Granule and Proteinuria
CHART-C3G/CLNP023B12011
KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Proteinuria in Pre and Post Transplant
Nefecon and Ambrisentan in IgA Nephropathy
Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease
Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease
Effects of Exogenous Ketosis on Proteinuria and Renal Function
Sitaxsentan in Proteinuric Chronic Kidney Disease